Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression

Chinese Medical Journal

Volumn 121, Issue 20, 2008, Pages 1975-1979

  Shi, Peng ^a   Wang, Ming Ming ^a   Jiang, Li Yu ^b   Liu, Huan Tao ^b   Sun, Jing Zhong ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Doxorubicin; Drug resistance; Heat shock protein 27; Paclitaxel

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; HEAT SHOCK PROTEIN 27; PACLITAXEL; ANTINEOPLASTIC AGENT; HSPB1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ASSAY; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG POTENTIATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; FEMALE; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; HSP27 HEAT-SHOCK PROTEINS; HUMANS; PACLITAXEL;

EID: 58749109629     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200810020-00005     Document Type: Article

References (24)

1. Mamounas EP. Present state and future prospects: a review of cooperative groups' adjuvant and neoadjuvant trials in breast cancer. Clin Breast Cancer 2001; 2 Suppl 1: s20-s30.
2. Kampinga HH, Brunsting JF, Stege GJ, Burgman PW, Konings AW. Thermal protein denaturation and protein aggregation in cells made thermotolerant by various chemicals: role of heat shock proteins. Exp Cell Res 1995; 219: 536-546.
3. Stege GJ, Kampinga HH, Konings AW. Heat-induced intranuclear protein aggregation and thermal radiosensitization. Int J Radiat Biol 1995; 67: 203-209.
4. Lelj-Garolla B, Mauk AG. Self-association and chaperone activity of HSP27 are thermally activated. J Biol Chem 2006; 281: 8169-8174.
5. Rau B, Gaestel M, Wust P, Stahl J, Mansmann U, Schlag PM, et al. Preoperative treatment of rectal cancer with radiation, chemotherapy and hyperthermia: analysis of treatment efficacy and heatshock response. Radiat Res 1999; 151: 479-488.
6. Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ, McGuire WL. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 1992; 52: 3648-3654.
7. Wu W, Welsh MJ. Expression of the 25-kDa heat-shock protein (HSP27) correlates with resistance to the toxicity of cadmium chloride, mercuric chloride, cis-platinum (II)-diamine dichloride, or sodium arsenite in mouse embryonic stem cells transfected with sense or antisense HSP27 cDNA. Toxicol Appl Pharmacol 1996; 141: 330-339.
8. Parsell DA, Lindquist S. The function of heat-shock proteins in stress tolerance: Degradation and reactivation of damaged proteins. Annu Rev Genet 1993; 27: 437-496.
9. Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. The small heat shock protein HSP27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 1993; 53: 4443-4448.
10. Yang YX, Xiao ZQ, Chen ZC, Zhang GY, Yi H, Zhang PF, et al. Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics 2006; 6: 2009-2021.
11. Tanaka Y, Fujiwara K, Tanaka H, Maehata K, Kohno I. Paclitaxel inhibits expression of heat shock protein 27 in ovarian and uterine cancer cells. Int J Gynecol Cancer 2004; 14: 616-620.
12. Zoli W, Ulivi P, Tesei A, Fabbri F, Rosetti M, Maltoni R, et al. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res 2005; 7: R681-689.
13. Chou TC, Talalay P. Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
14. Ioachim E, Tsanou E, Briasoulis E, Batsis Ch, Karavasilis V, Charchanti A, et al. Clinicopathological study of the expression of HSP27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast 2003; 12: 111-119.
15. Geisler JP, Tammela JE, Manahan KJ, Geisler HE, Miller GA, Zhou Z, et al. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up. Eur J Gynaecol Oncol 2004; 25: 165-168.
16. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000; 60: 7099-7105.
17. Kapranos N, Kominea A, Konstantinopoulos PA, Savva S, Artelaris S, Vandoros G, et al. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol 2002; 128: 426-432.
18. Thanner F, Sutterlin MW, Kapp M, Rieger L, Morr AK, Kristen P, et al. Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients. Anticancer Res 2005; 25: 1649-1653.
19. Concannon CG, Gorman AM, Samali A. On the role of Hsp27 in regulating apoptosis. Apoptosis 2003; 8: 61-70.
20. Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG, Fuqua SA. HSP27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 1999; 56: 187-196.
21. Song H, Ethier SP, Dziubinski ML, Lin J. Stat3 modulates heat shock 27kDa protein expression in breast epithelial cells. Biochem Biophys Res Commun 2004; 314: 143-150.
22. Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, et al. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 2003; 39: 2439-2449.
23. Sledge GW Jr. Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies. Semin Oncol 1996; 23 (5 Suppl 11): 57-59.
24. Danesi R, Conte PF, Del Tacca M. Pharmacokinetic optimization of treatment schedules for anthracyclines and Paclitaxel in patients with cancer. Clin Pharmacokinet 1999; 37: 195-211.